Results 31 to 40 of about 11,948 (164)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids

Rheumatology and Therapy, 2018
Introduction This study assessed if concomitant use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or corticosteroids altered the response or safety outcomes to baricitinib in rheumatoid arthritis (RA) patients.
Ronald van Vollenhoven, Cameron Helt, Vipin Arora, Jinglin Zhong, Ana Pinto Correia, Inma de la Torre, David Muram   +6 more
doaj   +1 more source

A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

Trials, 2023
Background Primary Sjogren’s syndrome (pSS) is a systemic autoimmune disease involving multiple organ systems. The Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway is a key pathway involving the pathogenesis of
Wei Bai, Fan Yang, Huji Xu, Wei Wei, Hongbin Li, Liyun Zhang, Yi Zhao, Xiaofei Shi, Yan Zhang, Xiaofeng Zeng, Xiaomei Leng   +10 more
doaj   +1 more source

Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19 patients with hyperinflammatory response; however, there is a lack of systematic review directly evaluating their efficacy and safety.Objective: This review was ...
Jin Zhang, Jin Zhang, Xiongxiong Fan, Xiaoyu Zhang, Fengli Jiang, Yiping Wu, Beibei Yang, Xinghuan Li, Dong Liu, Dong Liu   +9 more
doaj   +1 more source

Single‐Cell RNA Sequencing Informs Precision Targeting of Monogenic Lupus Associated With IKZF1 Haploinsufficiency

Arthritis &Rheumatology, EarlyView.
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng, Yejun Tan, Zhaoling Wang, Yanjie Qian, Qian Ma, Danping Shen, Meiping Lu   +6 more
wiley   +1 more source

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

Arthritis Research & Therapy, 2017
Background This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional ...
Michael Schiff, Tsutomu Takeuchi, Roy Fleischmann, Carol L. Gaich, Amy M. DeLozier, Douglas Schlichting, Wen-Ling Kuo, Ji-Eon Won, Tara Carmack, Terence Rooney, Patrick Durez, Saeed Shaikh, Rodolfo Pardo Hidalgo, Ronald van Vollenhoven, Cristiano A. F. Zerbini   +14 more
doaj   +1 more source

Investigating the role of Type I Interferon Signaling on Muscle Disease using mouse models

Arthritis &Rheumatology, Accepted Article.
Objective Dysregulated type I interferon (IFN) signaling contributes to autoimmune myositis pathogenesis. We investigated the therapeutic effects of JAK inhibitors in two mouse models. We also examined how type I IFNs affect muscle vasculature. Methods Myositis was induced in MHC class I transgenic (HT) female mice at day 21.
Rita Spathis, Sabrina Narvesen, Deeva Robles Kuriplach, Karen Huang, Teja Sundar, Elizabeth Bagley, Joanna E Parkes, Xinyu Jia, Nandhana Sudhan, Alfredo Guzman, Kanneboyina Nagaraju, Melissa Morales   +11 more
wiley   +1 more source

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long‐term multicenter observational study

Arthritis &Rheumatology, Accepted Article.
Objective Osteoporosis causes fractures which further increase the disease burden of rheumatoid arthritis (RA), however, osteoporosis treatment rates remain low. While several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh‐Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Hiroaki Tanaka, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka   +30 more
wiley   +1 more source

Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib

Dermatology and Therapy
Introduction Alopecia areata (AA) is an autoimmune disease associated with high rates of emotional and psychosocial distress. The analysis reported here describes the evolution of measures assessing health-related quality of life (HRQoL) and symptoms of ...
Brittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, Alexander Egeberg, Yves Dutronc, Frederick Durand, Evangeline Pierce, Guanglei Yu, Yun-Fei Chen, Arash Mostaghimi   +9 more
doaj   +1 more source

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

EBioMedicine, 2015
Background: Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA.
Ali Jabbari, Zhenpeng Dai, Luzhou Xing, Jane E. Cerise, Yuval Ramot, Yackov Berkun, Gina A. Montealegre Sanchez, Raphaela Goldbach-Mansky, Angela M. Christiano, Raphael Clynes, Abraham Zlotogorski   +10 more
doaj   +1 more source

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study

Medicina, 2022
Background and Objectives: Tocilizumab and baricitinib have been observed to improve the outcomes of patients with coronavirus disease 2019 (COVID-19). However, a comparative evaluation of these drugs has not been performed.
Yuichi Kojima, Sho Nakakubo, Nozomu Takei, Keisuke Kamada, Yu Yamashita, Junichi Nakamura, Munehiro Matsumoto, Hiroshi Horii, Kazuki Sato, Hideki Shima, Masaru Suzuki, Satoshi Konno   +11 more
doaj   +1 more source